Australia offers all adults AstraZeneca to speed up rollout

Australia is offering AstraZeneca to all adults to rapidly ramp up sluggish vaccination rates as more of the country locks down against COVID-19

Via AP news wire
Tuesday 29 June 2021 07:15
Virus Outbreak Australia
Virus Outbreak Australia

Australia is offering AstraZeneca to all adults in a bid to rapidly ramp up sluggish vaccination rates as more of the country on Tuesday locked down against the spread of COVID-19.

The government late Monday agreed to indemnify doctors who administer the AstraZeneca vaccine that has been blamed for at least two fatalities from a rare blood clot complication in Australia since April.

That exceeds the single death from COVID-19 in Australia this year, and vaccine hesitancy has increased with only 5% of the population fully inoculated.

Pfizer has been the recommended vaccine for people younger than 60 since a 52-year-old woman died in May of blood clots in the brain blamed on AstraZeneca.

But supply of Pfizer, the only alternative to Australian-manufactured AstraZeneca, cannot keep up with demand.

“There’s a preference for Pfizer until the age of 60. That’s a preference,” Chief Medical Officer Paul Kelly said on Tuesday.

“It’s a discussion for doctors to have with their own patients and work through their own risk and benefit in relation to that,” Kelly added.

The Queensland state capital Brisbane and surrounding cities will be in lockdown for three days from late Tuesday after the government reported two new COVID-19 infections.

Sydney reported 19 new infections in that east coast city, Perth reported two new cases on the west coast and Darwin reported two new cases on the north coast. Those three cities and their surrounds are already in lockdown.

Australia has been relatively successful in containing clusters throughout the pandemic, registering fewer than 31,000 cases and 910 deaths within a population of 26 million. But the new clusters of a variant thought to be more contagious have highlighted the nation’s vulnerability through a slow vaccine rollout.

AstraZeneca was supposed to be the mainstay of Australia’s vaccination rollout free of the uncertainties of international supply chains. It was recommended for all adults until a 48-year-old woman died of blood clots in April four days after her first jab. AstraZeneca was then said to be a safe option for adults aged over 50 until the 52-year-old died.

Some epidemiologists argue the government should speed up the rollout by reducing the gap between AstraZeneca jabs from 12 to eight weeks. But some Australians are now refusing to take a second shot because of the evolving perception of the blood clotting risk.

The New South Wales state government is highlighting vaccines’ apparent successes in the current Sydney cluster.

Twenty-four people who attended a birthday party on June 19 became infected with the delta variant. None had been vaccinated. But six fully vaccinated health workers and an aged care worker who had received the first of two doses attended the house party and were not infected.

“The early and strong indications from that party ... are, if you’re vaccinated, you are much more likely to not be infected with COVID-19,” Health Minister Brad Hazzard said on Monday.

State Agriculture Minister Adam Marshall said he was the only one among four government colleagues who dined together at a Sydney pizza restaurant on June 21 to become infected. An infected person had been at the restaurant earlier.

Marshall revealed he was the only one among the four who had not had a dose of vaccine because, at age 36, he was not eligible.

Register for free to continue reading

Registration is a free and easy way to support our truly independent journalism

By registering, you will also enjoy limited access to Premium articles, exclusive newsletters, commenting, and virtual events with our leading journalists

Please enter a valid email
Please enter a valid email
Must be at least 6 characters, include an upper and lower case character and a number
Must be at least 6 characters, include an upper and lower case character and a number
Must be at least 6 characters, include an upper and lower case character and a number
Please enter your first name
Special characters aren’t allowed
Please enter a name between 1 and 40 characters
Please enter your last name
Special characters aren’t allowed
Please enter a name between 1 and 40 characters
You must be over 18 years old to register
You must be over 18 years old to register
Opt-out-policy
You can opt-out at any time by signing in to your account to manage your preferences. Each email has a link to unsubscribe.

By clicking ‘Create my account’ you confirm that your data has been entered correctly and you have read and agree to our Terms of use, Cookie policy and Privacy notice.

This site is protected by reCAPTCHA and the Google Privacy policy and Terms of service apply.

Already have an account? sign in

By clicking ‘Register’ you confirm that your data has been entered correctly and you have read and agree to our Terms of use, Cookie policy and Privacy notice.

This site is protected by reCAPTCHA and the Google Privacy policy and Terms of service apply.

Register for free to continue reading

Registration is a free and easy way to support our truly independent journalism

By registering, you will also enjoy limited access to Premium articles, exclusive newsletters, commenting, and virtual events with our leading journalists

Already have an account? sign in

By clicking ‘Register’ you confirm that your data has been entered correctly and you have read and agree to our Terms of use, Cookie policy and Privacy notice.

This site is protected by reCAPTCHA and the Google Privacy policy and Terms of service apply.

Thank you for registering

Please refresh the page or navigate to another page on the site to be automatically logged inPlease refresh your browser to be logged in